Skip to content

ResMed RMD Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Gross margin234.2%+11.4pp222.8%-2.8pp225.6%-0.8pp226.4%-5.8pp
Operating margin126%+19.9pp106.1%-4.1pp110.3%-2.2pp112.5%-1.1pp
Net margin101.9%+18.7pp83.2%-2.8pp85.9%+12.1pp73.9%-0.8pp
EBITDA margin140.7%+18.9pp121.8%-4.6pp126.5%-4.2pp130.7%-3.2pp
Free cash flow margin119.9%+28.4pp91.5%+52.2pp39.3%-2.8pp42.1%-50.5pp
Returns
Return on equity100.9%+10.5pp90.3%-5.4pp95.8%+9.9pp85.9%-5.8pp
Return on assets70.6%+13.1pp57.5%-2.6pp60.1%+5.9pp54.2%+2.8pp
Return on invested capital92.7%+19.6pp73.1%-4.9pp78%+5.4pp72.6%+1.6pp
Efficiency
Asset turnover2.8×0.0×2.8×0.0×2.8×-0.1×2.9×+0.2×
Inventory turnover9.3×+0.6×8.7×+0.1×8.6×-2.4×11×-1.2×
Liquidity
Current ratio13.1×+1.4×11.7×-0.6×12.3×+1.9×10.4×+1.9×
Quick ratio9.2×+1.9×7.3×+0.2×7.1×+0.5×6.5×+0.7×
Cash ratio3.3×+2.1×1.1×-0.1×1.2×-0.2×1.5×-0.3×
Leverage
Debt-to-equity0.6×-0.5×1.1×-0.5×1.6×+0.5×1.1×-0.3×
Debt-to-assets0.5×-0.3×0.7×-0.2×+0.2×0.7×-0.1×
Net debt / EBITDA0.2×-2.8×-1.3×4.3×+2.0×2.3×-0.2×
Per Share
Book value per share$148.99+20.6%$123.56+19.5%$103.38+18.6%$87.17+14.4%
Valuation
Market capitalization$139.84B+34.1%$104.29B-17.7%$126.78B-11.0%$142.49B+18.6%
Enterprise value$140.17B+29.3%$108.36B-18.0%$132.08B-9.0%$145.13B+18.2%
Price / earnings110.9×+0.6×110.3×-41.1×151.4×-83.0×234.4×+15.8×
Price / sales28.1×+5.2×22.9×-9.6×32.5×-8.5×41.1×+2.4×
Price / book25.5×+2.7×22.8×-10.6×33.4×-11.3×44.7×+1.7×
EV / EBITDA80.3×+2.0×78.3×-28.9×107.2×-20.8×128×+9.9×
EV / sales28.2×+4.3×23.8×-10.1×33.9×-7.9×41.8×+2.3×
Free cash flow yield17.1%+1.2pp15.9%+11.0pp4.9%+0.9pp4%-5.7pp
Earnings yield14.6%-0.1pp14.6%+4.0pp10.6%+3.2pp7.4%-0.5pp
Dividend yield3.4%-0.8pp4.2%+1.0pp3.2%+0.5pp2.7%-0.4pp
PEG ratio3.5×-5.7×9.2×+1.9×7.2×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are ResMed's profit margins?
ResMed (RMD) runs a 61.6% gross margin and a 34.2% operating margin, with a 27.4% net margin.
Where do ResMed's ratios come from?
Every ratio is computed from ResMed's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.